Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898399 · ClinicalTrials.gov registry record · Phase 1

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Artios Pharma.

Active
Registry status
Phase 1
Development phase
220
Enrollment target
7
Study locations

NCT05898399 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is active but no longer recruiting, run by Artios Pharma. The registered enrollment target is 220 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898399, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is active but no longer recruiting, sponsored by Artios Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
7
Study locations

Study Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Olaparib
  • DRUG ART6043

Study Locations (7)

Texas

  • Mary Crowley Cancer Center - Clinic - Dallas
  • The University of Texas - MD Anderson Cancer Center - Houston

Michigan

  • South Texas Accelerated Research Therapeutics (START) - Midwest - Grand Rapids

New York

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

Oklahoma

  • Stephenson Cancer Center - Oncology - Oklahoma City

Pennsylvania

  • Jefferson University Hospitals - Kimmel Cancer Center - Philadelphia

Tennessee

  • SCRI oncology partners - Nashville

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2023-06-30
Est. Completion 2026-12-14
Phase Phase 1

Sponsor

Artios Pharma

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05898399

The ClinicalTrials.gov registry entry for NCT05898399 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The listed sponsor is Artios Pharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT05898399 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT05898399 about?

NCT05898399 is a clinical study titled "Study of ART6043 in Advanced/Metastatic Solid Tumors Patients". This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

What is the current status of trial NCT05898399?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2023-06-30. Estimated completion is 2026-12-14.

What conditions does trial NCT05898399 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT05898399?

The interventions under investigation include: Olaparib (DRUG), ART6043 (DRUG).

Who is sponsoring clinical trial NCT05898399?

This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898399 being conducted?

This trial has 7 study locations across Michigan, New York, Oklahoma, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.